Inhibition of p38 kinase blocks the production of tumorpromoting factors in the multiple myeloma (MM) bone marrow microenvironment. Proteasome inhibitors MG132 and bortezomib have been shown to have direct cytotoxic effects on MM cells. We show that a selective inhibitor of p38a, SCIO-469, enhances the ability of MG132 and bortezomib to induce the apoptosis of MM cells. Previously, we showed that p38 inhibition with SCIO-469 enhances MM cytotoxicity of bortezomib by inhibiting the transient expression and phosphorylation of Hsp27, a downstream target of p38. Here we show that continued treatment of MM cells with bortezomib leads to a SCIO-469-enhanced downregulation of Hsp27 and to increased MM apoptosis. Furthermore, we show that p38 inhibition enhances the bortezomib-induced MM apoptosis by upregulation of p53 and downregulation of Bcl-X L and Mcl-1. In a mouse xenograft plasmacytoma model of MM, we found that inhibiting p38 augments the effects of bortezomib in decreasing MM tumor growth in vivo. Thus, in addition to its role in suppressing an activated MM microenvironment, co-treatment with a p38 inhibitor, such as SCIO-469, may enhance the cytotoxicity of bortezomib by modulating pro-apoptotic and anti-apoptotic factors in MM cells, suggesting great potential for co-therapy.
Introduction
Multiple myeloma (MM) is a plasma-cell malignancy that remains incurable despite conventional treatment and recent advances in novel therapies. 1 The interaction of MM cells with bone marrow stromal cells (BMSC) triggers the production by BMSC of cytokines such as IL-6 2 and VEGF, 3 which promote MM cell survival. Mitogen-activated protein kinase (MAPK) p38a mediates the cellular response to stress and is activated by pro-inflammatory cytokines such as tumor necrosis factor a (TNF-a) and interleukin-1b (IL-1-b). 4 Activation of p38 in BMSC enhances the production of IL-6, which is crucial for MM growth. 5 In addition, p38 activation induces cytokines that promote osteoclast differentiation, likely contributors to the osteolytic lesions characteristic of MM. 6 p38 inhibition suppresses the tumor-supportive state of BMSC in culture and has been proposed as a novel treatment for MM. 5 As p38 inhibition targets the microenvironment, co-therapy with agents targeting MM tumor cells has been suggested as an attractive treatment option.
Recently we reported that SCIO-469, a potent and specific inhibitor of p38a, augments the cytotoxicity of bortezomib against MM cell lines and patient MM cells. 7 In fact, SCIO-469 was found to restore the sensitivity of bortezomib-resistant MM patient cells to bortezomib. We showed that p38 inhibition by SCIO-469 enhanced the bortezomib-induced phosphorylation of c-Jun NH 2 -terminal kinase (JNK) and inhibited the bortezomib-induced upregulation of p21
Cip1 abolishing G1 cell-cycle arrest and leading to the accumulation of co-treated MM cells in the G2/M phase of the cell cycle. 7 Inhibition of p38 also increases bortezomib-induced MM cytotoxicity by inhibiting the induction and phosphorylation of Hsp27. Hsp27 is a stress protein with anti-apoptotic properties 8 and is regulated by p38 through MAPKAPK-2 activation. 9 Hsp27 acts as a molecular chaperone that can interfere with the mechanisms of caspase activation. During stress, the increase in Hsp27 levels is preceded by a phosphorylation-induced reorganization of the protein's multimeric status. 8 Hsp27 also has a role in conferring dexamethasone resistance to MM cells. 10 In addition, overexpression of Hsp27 confers bortezomib resistance to some lymphoma cells. 11 Treatment of MM cells with bortezomib leads to the transient induction of heat shock proteins, including Hsp27, 12 and co-treatment with SCIO-469 inhibits the initial expression and phosphorylation of Hsp27. 7 However, our recent flow cytometry data reveal that the early inhibition of Hsp27 expression by SCIO-469 did not directly correlate with the increased cytotoxicity of bortezomibtreated MM cells. Rather, we show here that continued treatment with bortezomib leads to the selective downregulation of Hsp27 in later time points and that p38 inhibition with SCIO-469 facilitates the reduction of Hsp27 induced by bortezomib. We further show that the enhancement of Hsp27 downregulation is paralleled by the increased activation of various caspases regulating cell death, and thus by increased apoptosis of MM cells.
In this report we also examined additional apoptotic pathways, independent of the Hsp27 pathway, that may be regulated by co-therapy with bortezomib and SCIO-469 in promoting MM cell death. Proteins in the Bcl-2 family are known to play a key role in regulating apoptosis. 13 The upregulation of antiapoptotic Bcl-2 family members such as Bcl-X L and Mcl-1 has been identified in MM.
14 Mcl-1 and Bcl-X L are known to promote tumor survival and to be prognostic indicators of MM disease severity. [15] [16] [17] [18] Mcl-1 expression has been associated with disease relapse and shortened survival in vivo 16 and specific Mcl-1 downregulation induced rapid apoptosis of human myeloma cells. 17 Bcl-X L has also been shown to promote MM cell resistance to chemotherapeutic drugs. 18 Whereas bortezomib treatment reduces the mRNA expression levels of Bcl-2 in MM, 12 the effect on protein expression of either Mcl-1 or Bcl-X L has not been reported. Here we show that co-treatment of MM cells with SCIO-469 and bortezomib leads to the enhanced reduction in the protein levels of Bcl-X L and Mcl-1, coincident with increased MM apoptosis. Additionally, we found that SCIO-469 enhanced the induction of the transcription factor p53 by bortezomib. Furthermore, to determine whether the enhanced cytotoxic effects of bortezomib and SCIO-469 cotreatment on MM cells in vitro is ultimately reflected in vivo, we developed a mouse MM plasmacytoma model and used it to test either single drug or combination therapy. We show here that SCIO-469 prevented MM tumor growth as single agent in vivo and, additionally, enhanced the anti-tumor effects of bortezomib as shown in vitro. Thus, co-treatment in an MM disease model with a p38 inhibitor and a proteasome inhibitor enhances MM tumor cell killing. Considered in addition to the beneficial effects on the microenvironment, the pro-apoptotic combination offers attractive therapeutic potential.
Materials and methods

Materials
p38a MAPK inhibitor SCIO-469 was synthesized by Medicinal Chemistry (Scios, Inc., Fremont, CA, USA). SCIO-469 has an IC 50 of 9 nM for inhibition of p38a based on direct enzymatic assays, about 10-fold selectivity for p38a over p38b, and at least 2000-fold selectivity for p38a over a panel of 20 other kinases, including other MAPKs. No significant affinity was detected in a panel of 70 enzymes and receptors. In a cell-based assay for inhibition of LPS-induced TNF-a secretion in whole human blood, an IC 50 of 1.3 mM is observed. Bortezomib was purchased from Millenium (Cambridge, MA, USA) and MG132 from Oncogene (San Diego, CA, USA). Specific antibodies to p38, Hsp70, Hsp90 and Mcl-1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to phospho-p38 (T180/ Y182), phospho-Hsp27 (S82), caspase-3, -6, -7, -8, -9, PARP, p53 and Bcl-X L were from Cell Signaling (Beverly, MA, USA). Antibodies to Hsp27 and phospho-Hsp27 (S78) were from Upstate Biotechnology (Lake Placid, NY, USA). Anti-MAPKAPK-2 was from StressGen (San Diego, CA, USA) while anti-GAPDH was from Biogenesis Ltd. (Poole, UK).
Cell lines and cell culture
U266B1 and RPMI8226 MM cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). IM9, an EBV-transformed B-cell line, was also obtained from ATCC. Cell lines were maintained in RPMI-1640 (ATCC) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 100 units/ml of penicillin and 100 mg/ml streptomycin. BMSC (Cambrex, Walkersville, MD, USA) were maintained in Myelocult H5100 supplemented with 10 À6 M hydrocortisone (Stem Cell Technologies, Vancouver, B.C. 
Apoptosis assay
Detection of apoptotic cells was performed by staining with Annexin V-Phycoerythrin (PE) (BD Pharmingen; San Diego, CA, USA). Samples were analyzed in triplicates using a FACScan laser flow cytometer and Cell Quest software (BD Bioscience, San Jose, CA, USA).
Kinase assay and Western analysis
MAPKAPK-2 activity in MM cells was determined with the MAPKAPK-2 kinase assay kit using GST-Hsp27 as substrate (Upstate Biotechnology). For Western analysis, MM cells were lysed in RIPA buffer and cell lysates were resolved by NuPAGE gels (Invitrogen), transferred onto nitrocellulose, immunoblotted using epitope-specific primary antibodies and HRP-conjugated secondary antibodies and then visualized using the ECL system (Pierce, Rockford, IL, USA).
Xenograft murine model
Triple immune-deficient BNX mice (Charles River, Wilmington, MA, USA) were inoculated subcutaneously (s.c.) into the right flank with 3 Â 10 7 RPMI8226 cells in 100 ml of RPMI-1640 media, together with 100 ml of matrigel basement membrane matrix (BD Bioscience). When tumors reached approximately 800 mm 3 , mice were assigned to four groups with each receiving vehicle, 30 mg/kg SCIO-469 orally twice daily, 0.2 mg/kg bortezomib intravenously twice weekly or a combination of both drugs. At the end of 27 days, the animals were killed, tumors were harvested and tumor weight was recorded.
Immunohistochemistry
Multiple myeloma tumor tissue was immunostained with primary antibodies to phospho-p38 (clone 12F8, Cell Signaling), activated caspase 3 (R&D Systems) or p53 (clone SP5, Lab Vision, Fremont, CA, USA) and with biotinylated goat antirabbit as secondary antibody (Chemicon, Temecula, CA, USA). Caspase 3 and p53 were quantified under 40 Â by calculating the ratio of the positively-stained tumor cells to the total number of tumor cells in the non-necrotic tumor area using an Image Pro Plus software.
Statistical analysis
One-way ANOVA with Bonferroni's or Dunnett's Multiple Comparison post test was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA).
Results
SCIO-469 blocks p38 activation and Hsp27 phosphorylation in U266, RPMI8226 and IM9 cells
Initially, we examined the phosphorylation of p38 in MM cell lines U266 and RPMI8226 as well as the EBV-transformed B cell line IM9, which has MM like characteristics. 19 Interestingly, we found that these cells have high basal p38 phosphorylation p38a inhibitor enhances apoptosis of myeloma cells by bortezomib TA Navas et al levels ( Figure 1a ). SCIO-469, a selective inhibitor of p38a, substantially suppressed p38 phosphorylation in all three cell lines ( Figure 1a ). SCIO-469 specifically blocks the catalytic activity of p38a and not the activity of upstream MAPKKs, MKK3 and MKK6 (see Materials and methods). Furthermore, SCIO-469 does not block the ability of p38 to act as a substrate for MKK3 and MKK6 (data not shown). Thus, the reduced p38 phosphorylation is most likely the result of a disrupted autocrine or autophosphorylation loop. Consistent with the ability of SCIO-469 to inhibit p38 kinase activity, SCIO-469 suppressed the activity of a downstream substrate MAPKAPK-2, as measured by in vitro kinase assay ( Figure 1b) . Finally, SCIO-469 inhibited Hsp27 phosphorylation, as determined by direct examination of cell lysates ( Figure 1c ). Whereas SCIO-469 inhibited Hsp27 phosphorylation, it did not affect total Hsp27 levels in these cells even after prolonged incubation with the p38 inhibitor ( Figure 1c ). These results demonstrate that SCIO-469 is an effective inhibitor of p38 MAP kinase activity. Inhibiting p38 with SCIO-469 in different MM cell lines has minimal acute effect on cell viability. 7 As the bone marrow secretes some p38-dependent MM survival factors, we further examined whether SCIO-469 has an additional effect on inhibiting the proliferation of MM cells when co-cultured with BMSC. As observed in the monoculture of U266, RPMI8226 or IM9 cells, only a slight effect on proliferation was observed when cocultures of BMSC and MM cells were treated with SCIO-469 for 72 h (Supplementary Figure S1 ).
Inhibition of p38 enhances MG132-induced MM cell death
We have recently shown that SCIO-469 enhanced the activity of the proteasome inhibitor bortezomib in inducing MM cytotoxicity. 7 Bortezomib is a potent and specific proteasome inhibitor (Ki ¼ 0.62 nM for the chymotrypsin-like activity of the proteasome) that was recently approved by the FDA for treatment of MM. We then asked whether the effect of SCIO-469 in enhancing MM cytotoxicity is unique only to bortezomib or whether the effect of SCIO-469 extends to other proteasome inhibitors. MG132 (Ki ¼ 4 nM) has a similar mechanism of proteasome inhibition as bortezomib. 20 We therefore examined the interaction of SCIO-469 and MG132 in inhibiting the metabolic activity and cell proliferation as well as in inducing the apoptosis of MM cells.
SCIO-469 significantly enhanced the activity of MG132 in reducing cell viability and proliferation of MM cells (Figure 2a) . Furthermore, the interaction between SCIO-469 and MG132 to enhance inhibition of cell proliferation was also apparent when each cell line is co-cultured with BMSC (Supplementary Figure S2) . To determine whether SCIO-469 enhanced MG132-induced MM apoptosis, we labeled RPMI8226 cells with Annexin-V-Phycoerythrin (PE), a marker of early apoptotic changes leading to cell death. Cells were analyzed by flow cytometry over a 36 h exposure period (Figure 2b ). Treatment with SCIO-469 alone has minimal effect on RPMI8226 cell viability during the entire time course. However, beginning at 16 h, the combination 
Enhancement of bortezomib-induced apoptosis by p38 inhibition correlates with the downregulation of Hsp27 in MM cells
Previously, we demonstrated that SCIO-469 enhanced bortezomib-induced toxicity in MM.1S, U266 and RPMI8226 cell lines and in MM patient cells, even in those patient cells that are resistant to bortezomib. 7 However, the effects of both drugs on MM cytotoxicity were examined only with the use of limited doses of either drug and only within a defined period. We found that increasing concentrations of SCIO-469 enhanced cytotoxicity in RPMI8226 and IM9 only within a very narrow dose range of bortezomib after 72 h (Figure 3a) . On the other hand, a wider (Figure 3b) . We then selected a fixed dose for each drug and monitored the rate of apoptosis in RPMI8226 cells in a time course experiment. The enhanced cytotoxic effect of the drug combination compared to bortezomib alone became apparent after 16 h of incubation (Figure 3c ). We initially hypothesized that the enhancement of bortezomib-induced MM apoptosis by SCIO-469 could be fully explained by the inhibition of the induced Hsp27 expression and phosphorylation by bortezomib. 7 However, previous results showed that Hsp27 expression was induced much earlier at 8 h 12 and may not correlate with the enhanced apoptosis we were seeing at much later time points in the experiment shown in Figure 3c . We therefore investigated whether inhibiting Hsp27 activity at much later time points could play a role in bortezomib-induced MM apoptosis. RPMI8226 cells were treated with either bortezomib or in combination with SCIO-469 and cells were analyzed for total Hsp27 and phosphoHsp27 at three different exposure times ( Figure 4) . As reported earlier in MM.1S cells, 12 some heat shock proteins including Hsp27 and Hsp70 were induced 8 h after bortezomib treatment in RPMI8226 cells. The induction of these proteins is likely a part of the stress response in reaction to the increased presence of unfolded intracellular proteins. However, continued bortezomib treatment resulted in the reduction of Hsp27, but not of Hsp70 or Hsp90, protein levels (Figure 4a) . Surprisingly, cotreatment with SCIO-469 enhanced the downregulation by bortezomib of total Hsp27 at 12 and 16 h in RPMI8226 (Figure 4b ) as well as in IM9 cells (data not shown). The decrease of phospho-Hsp27 levels in the bortezomib-treated cells was commensurate with the decrease of total Hsp27 protein in these cells. In addition, there was complete inhibition of Hsp27 phosphorylation at all time points examined after addition of both drugs (Figure 4a ).
To investigate whether the reduction of Hsp27 correlates with the increased cytotoxicity observed in MM cells, RPMI8226 cells were treated with SCIO-469 or bortezomib, either alone or in combination, and cells were examined for apoptosis at different timepoints by flow cytometry (Figure 5a ). As shown previously, combination treatment of bortezomib with SCIO-469 resulted in an increased proportion of apoptotic cells compared to treatment with bortezomib alone. Western-blot analysis of cell lysates showed successively increasing activation or cleavage of procaspases-8, -9, -3, -6, and -7 as well as PARP with increasing duration of bortezomib treatment (Figure 5b ). The activation of these apoptotic enzymes was coordinately enhanced by co-treatment with SCIO-469. Furthermore, a pan-caspase inhibitor Z-DEVD-FMK was able to block the apoptotic effect of either bortezomib or bortezomib and SCIO-469 on RPMI8226 cells (Figure 5c) . Notably, the increased caspase and PARP activation observed for each exposure time correlates with the decreasing levels of Hsp27 (Figure 5b ) and closely parallels the degree of apoptosis occurring in these cells (Figure 5a ). These results show that the downregulation of Hsp27 in RPMI8226 cells could lead to the enhanced cytotoxicity of MM cells in the combination therapy of bortezomib and SCIO-469.
Inhibition of p38 enhances the induction of p53 and downregulation of Bcl-X L and Mcl-1 by bortezomib in RPMI8226 cells
Hsp27 inhibits the intrinsic pathway of apoptosis by blocking the release of cytochrome c from the mitochondria and by preventing the formation of critical components of the apoptosome, thus negatively regulating the cascade of caspase activation beginning with procaspase-9 cleavage. 8 To investigate whether other apoptotic pathways upstream of this critical juncture are also regulated by bortezomib and SCIO-469 in promoting MM apoptosis, we examined by Western analysis cell lysates of MM cells treated with either or both of these drugs for levels of other known key apoptotic proteins. In parallel, we also examined these cells by flow cytometry to correlate the changes in protein levels with the degree of MM apoptosis achieved during the course of the experiment (Figure 6a) . Western-blot analysis reveals that bortezomib induced the expression of the proapoptotic transcription factor p53 and the downregulation of the anti-apoptotic protein Bcl-X L (Figure 6b ). The increase in the levels of p53 or the reduction of Bcl-X L levels was enhanced by SCIO-469 and also correlated with the increase in MM apoptosis. Interestingly, whereas treatment with SCIO-469 alone did not affect the levels of p53, p38 inhibition with SCIO-469 resulted in the downregulation of Bcl-X L levels.
We also examined the levels of the anti-apoptotic protein Mcl-1 and found that Mcl-1 L was cleaved by bortezomib treatment, possibly as a result of caspase 3 activation, 21 and that co-treatment with 
Inhibition of p38 inhibits MM tumor growth and enhances bortezomib-induced apoptosis of RPMI8226 cells in vivo
In order to determine whether the effects of SCIO-469 in enhancing bortezomib-induced MM apoptosis in vitro can be manifested in vivo, we developed a mouse plasmacytoma model of MM (see Materials and methods). Four groups of animals (n ¼ 5 per group) were treated either with vehicle, 30 mg/kg SCIO-469 orally twice daily, 0.2 mg/kg of bortezomib intravenously (i.v.) twice weekly or a combination of both drugs. The study was terminated after 27 days and tumors were weighed (Figure 7a ) and examined by immunohistochemistry (IHC) for apoptotic markers (Figure 7b and c) . Surprisingly, animals treated with SCIO-469 alone showed a significant effect in inhibiting MM tumor weight (Po0.01) compared to vehicle after 27 days. Expectedly, bortezomib treatment also led to a significant reduction in tumor weight (Po0.01) compared to vehicle. Furthermore, co-treatment with both drugs led to a significantly enhanced effect in reducing tumor weight compared to vehicle (Po0.001) or compared to either p38a inhibitor enhances apoptosis of myeloma cells by bortezomib TA Navas et al Evaluation of the tumor tissues derived from these animals by IHC revealed that p38 phosphorylation was markedly inhibited only in animals that received SCIO-469, whether alone (Po0.01) or with the drug combination (Po0.001), as compared to vehicle-treated animals (data not shown). As determined by IHC, the extent of tumor necrosis did not differ significantly between any of the groups (data not shown). In contrast, elevation of apoptosis correlated inversely with tumor size. Caspase-3 activation in MM tumor cells was elevated only in the combination treatment group compared to vehicle treatment (Po0.05) (Figure 7b) . A trend towards elevation of activated caspase-3 in MM tumor cells was seen in both the SCIO-469 or bortezomib-treated groups compared to vehicle-treated group, but this effect was not statistically significant. Finally, p53 in MM tumor cells was significantly upregulated only in the SCIO-469/bortezomib combination-treated group (Po0.05) compared to vehicletreated group, but not significantly upregulated in those treated either with SCIO-469 or bortezomib alone (Figure 7c) . These results reveal that treatment with the combination of SCIO-469 and bortezomib significantly inhibits tumor growth compared to single drug therapy and that the induction of MM apoptosis correlates with enhanced caspase activation and p53 induction in vivo, thus confirming the results that we have shown in vitro.
Discussion
A serious impediment to treatment of multiple myeloma is the propensity for patients to develop resistance to current therapies. The proteasome inhibitor bortezomib has shown remarkable anti-tumor activity in some relapsed refractory MM patients. 22 However, about two-thirds of patients do not respond to this therapy and most who do eventually develop resistance to bortezomib. The elucidation, therefore, of the mechanisms by which proteasome inhibitors like bortezomib promote MM apoptosis could provide the basis for developing alternative strategies for enhancing treatment effectiveness and durability through combination with other therapies.
The present results show that combined exposure of multiple myeloma cells to proteasome inhibitors such as MG132 or bortezomib and to the p38 MAPK inhibitor SCIO-469 leads to an enhanced apoptosis of MM cells by bortezomib (Figures 2  and 3 ). Inhibiting p38 MAP kinase augments the downregulation of the anti-apoptotic protein Hsp27 (Figure 4 ) and induces MM cytotoxicity by enhancing the bortezomib-induced activation of various caspases and PARP ( Figure 5 ). In addition, increased apoptosis of MM cells correlated with the reduction in the levels of the anti-apoptotic proteins Bcl-X L and Mcl-1 and in the induction of the pro-apoptotic transcription factor p53 ( Figure 6 ). Furthermore, we have shown that the combined therapy leads to enhanced inhibition of MM tumor growth and to increased caspase activation and p53 accumulation in the MM tumor cells in vivo (Figure 7 ). p38 MAP kinase plays an anti-apoptotic role in a number of cell types. 23, 24 In multiple myeloma, inhibition of p38 MAP kinase has been previously shown to abrogate IL-6 and VEGF secretion from BMSC. 9 Treatment with SCIO-469 of MM cells alone or in co-culture with BMSC did not lead to an appreciable decrease in MM cell viability under normal in vitro culture conditions (Supplementary Figure S1) . However, our recent data with long-term cell cultures (7 days) of RPMI8226 cells and BMSC in transwell plates reveal that suppression of supportive factors from BMSC leads to the enhanced inhibition of RPMI8226 cell proliferation. 25 Furthermore, in our animal model, we saw a significant effect of SCIO-469 alone in inhibiting MM tumor growth. The effect of inhibiting p38 in this case is probably not a direct effect on MM cells, but rather an indirect effect by inhibiting production of supporting factors by the host. SCIO-469, however, potentiates the direct cytotoxic effects of bortezomib on MM cells in vitro through the induction of various apoptotic pathways regulated by Hsp27, 13, 14 by the Bcl-2 family members Bcl-X L 15,18 and Mcl-1 16, 17, 27 and also by p53. 26 In the histological analysis of our mouse model, the only tumor cells examined were those which had survived the 27-day drug-treatment regimen, whereas acute responses to treatment were assessed in vitro.
Microarray analysis has shown that bortezomib downregulates the expression of several anti-apoptotic genes such as Bcl-2, A1, cIAP-2, FLIP and XIAP. 12 Bortezomib also upregulates pro-apoptotic genes such as p53, 26 Bax, caspase-8, -9, -1, -7, -4 and -5, death-inducing receptors DR5 and Fas, as well as the death ligand FasL. 27 Bortezomib has also been shown to acutely upregulate several heat shock proteins including Hsp27, presumably as a normal stress response. 12 However, at subsequent times which correspond to initiation and execution of apoptosis in MM cells, we have shown a specific correlation of enhanced apoptosis with decreased Hsp27 levels (Figure 5b ) while other heat shock proteins such as Hsp70 and Hsp90 remain unaltered (Figure 4 ). In addition, we have shown p38a inhibitor enhances apoptosis of myeloma cells by bortezomib TA Navas et al that two key anti-apoptotic members of the Bcl-2 family, Bcl-X L and Mcl-1, are also downregulated at the protein level by bortezomib treatment. Bortezomib-induced changes in transcription levels of these two proteins were not previously seen in microarray studies with MM.1S 12 and in RPMI8226 cells (unpublished results) suggesting that the downregulation of these proteins may occur post-transcriptionally. 28, 29 The enhancement of the downregulation of Hsp27, Mcl-1 and Bcl-X L proteins by p38 inhibition with various apoptotic agents has been previously shown in other cell types and is likely due to various mechanisms. [29] [30] [31] Inhibiting p38 with SCIO-469 reduces Hsp27 phosphorylation (Figure 1b) but inhibiting Hsp27 phosphorylation alone may not be sufficient to induce MM cytotoxicity (Figures 4 and 5) . However, SCIO-469 may diminish Hsp27 levels as a direct consequence of inhibiting Hsp27 phosphorylation in MM cells, as reported in neutrophils. 30 Also, it has been shown in human keratinocytes that UVA treatment results in the activation of p38 which is required to maintain the stability of Bcl-X L after DNA damage. 29 Bortezomib induces p38 activity in MM cells 7 and p38 may be similarly required to maintain the stability of Bcl-X L in response to bortezomib. In this report we showed that inhibiting p38 with SCIO-469 alone also leads to the downregulation of Bcl-X L without bortezomib treatment indicating that Bcl-X L stability is dependent on p38 activity in MM. In polymorphonuclear leukocytes (PMNs), hypoxia was found to induce Mcl-1 protein levels and inhibiting p38 led to the downregulation of Mcl-1 and to increased PMN apoptosis. 31 We previously showed that acute exposure to SCIO-469 enhances the bortezomib-induced phosphorylation of c-Jun NH 2 -terminal kinase (JNK) and inhibited the bortezomibinduced upregulation of p21 Cip1 . 7 In this report, we showed that the bortezomib-induced accumulation of p53 was enhanced by continued exposure to SCIO-469 and that increased p53 correlated with increased apoptosis of MM cells both in vitro and in vivo. The induction of p53 may lead to the increased transcription of other pro-apoptotic proteins such as the BH3-only protein Puma 32 which in turn could lead to the enhanced expression and translocation of Bax to the mitochondria and reduce the mitochondrial membrane potential (DC m ) thereby enhancing its permeability. 33, 34 The increased downregulation of Bcl-X L and Mcl-1 by p38 inhibition further promotes mitochondrial cytochrome c release 35 whereas the downregulation of Hsp27 leads to enhanced activation of various caspases and PARP to enhanced MM apoptosis. 8 Thus, in addition to the complementary effects of the p38 inhibitor, SCIO-469, and bortezomib in blocking microenvironment production of supporting factors for MM cell growth, the combined therapy with SCIO-469 enhances the cytotoxic effects of bortezomib by regulating both pro-apoptotic and anti-apoptotic factors in MM cells, providing a preclinical basis for an improved therapy for multiple myeloma.
